Vikas Kalra
Nephrology · Scottsdale, AZNPI 1801041041
Payments from drug & device makers
Across 99 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$447
- AstraZeneca$312
- Otsuka America Pharmaceutical, Inc.$209
- OPKO Pharmaceuticals, LLC$169
- Bayer$141
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$129
- plus $677 from 18 others
What the payments were for
- Food & beverage$1,97095%
- Education$1145%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 20 | $447 |
| AstraZeneca(2 entities) | 13 | $312 |
| Otsuka America Pharmaceutical, Inc. | 14 | $209 |
| OPKO Pharmaceuticals, LLC | 9 | $169 |
| Bayer | 6 | $141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $129 |
| Calliditas Therapeutics US Inc. | 3 | $82 |
| Aurinia Pharma U.S., Inc. | 3 | $68 |
| Novartis | 4 | $65 |
| Abbott | 2 | $48 |
| Boehringer Ingelheim | 2 | $40 |
| Mallinckrodt Enterprises LLC | 2 | $39 |
| GSK | 2 | $37 |
| Abiomed | 2 | $37 |
| Vifor Pharma, Inc. | 2 | $35 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 1 | $34 |
| Cormedix Inc. | 1 | $28 |
| Travere Therapeutics, Inc. | 3 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| Renalytix AI, Inc. | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Sanofi | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$118
How this compares
$2,084 in reported general payments places this provider in the 45th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 23 | $34,160 |
| Tolvaptan | 13 | $4,966 |
| Potassium Citrate ErPotassium Citrate | 23 | $2,893 |
| Bumetanide | 20 | $1,680 |
| Calcitriol | 74 | $1,234 |
| Potassium Chloride | 21 | $1,025 |
| Doxazosin Mesylate | 56 | $827 |
| Tamsulosin Hcl | 40 | $807 |
| Nifedipine ErNifedipine | 16 | $775 |
| Losartan Potassium | 51 | $705 |
| Amlodipine Besylate | 112 | $688 |
| Hydrochlorothiazide | 109 | $620 |
| Carvedilol | 57 | $522 |
| Hydralazine Hcl | 27 | $382 |
| Lisinopril | 70 | $377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $312 | $34,16023 claims |
| Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan | $35 | $4,96613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 259 nephrology providers in Arizona.
Other nephrology in Scottsdale
- Evamaria AnvariScottsdale$263K
- Ethel WeilScottsdale$73K
- Saeed ShaffiScottsdale$64K
- Musab HommosScottsdale$49K
- Sami AlasfarScottsdale$35K
- Girish MourScottsdale$29K
- Alejandro MoralesScottsdale$13K
- Kaleem AslamScottsdale$9K
- Divya MalladiScottsdale$7K
- Peter SantosGlendale$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.